Maxim Lifts PT on Inovio (INO) to $23 Following Initiation of Dosing in PENNVAX-GP Phase 1
Tweet Send to a Friend
Maxim Group lifts its price target on Inovio Pharmaceuticals (Nasdaq: INO) from $20 to $23 and affirms its Buy rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
